Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session



  • Swvl Holdings Corp. SWVL surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.
  • Spruce Biosciences, Inc. SPRB shares jumped 100.8% to $2.51. Spruce Biosciences and Kaken Pharmaceutical reported an exclusive licensing agreement to develop and commercialize Tildacerfont for CAH in Japan.
  • MedAvail Holdings, Inc. MDVL gained 54% to $0.4745. MedAvail Holdings, during November, posted a Q3 loss of $0.15 per share.
  • CytomX Therapeutics, Inc. CTMX climbed 46.4% to $2.6198. CytomX and Moderna reported a strategic research collaboration for mRNA-based conditionally activated therapeutics.
  • Zomedica Corp. ZOM gained 38% to $0.2649 after Dawson James initiated coverage on the stock with a Buy rating and a $6 price target.
  • Aehr Test Systems AEHR shares jumped 34.8% to $23.28 after the company reported better-than-expected Q2 EPS and sales results and announced it received a follow-on production order from its second major silicon carbide semiconductor customer for an additional production FOX-XP multi-wafer test and burn-in system configured with Aehr's fully integrated and automated WaferPak Aligner.
  • Tantech Holdings Ltd TANH gained 26.8% to $3.1980. Tantech Hldgs recently posted H1 sales of $27.00 million.
  • Tonix Pharmaceuticals Holding Corp. TNXP gained 26% to $0.7555.
  • Aligos Therapeutics, Inc. ALGS jumped 23.2% to $1.22 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $2.5 to $3.
  • Infobird Co., Ltd IFBD surged 23% to $0.9476.
  • Kidpik Corp. PIK gained 22.2% to $0.8799.
  • Sight Sciences, Inc. SGHT gained 21.8% to $14.39. Stifel upgraded Sight Sciences from Hold to Buy and raised the price target from $10 to $15.
  • Mobile Global Esports Inc. MGAM rose 21.5% to $1.30 after gaining over 21% on Thursday.
  • Schmitt Industries, Inc. SMIT gained 21.3% to $0.3399.
  • EZGO Technologies Ltd. EZGO gained 19.5% to $0.99.
  • Zynex, Inc. ZYXI gained 19.4% to $16.89. Piper Sandler upgraded Zynex from Neutral to Overweight and raised the price target from $10 to $18.
  • CureVac N.V. CVAC surged 18.2% to $7.54 after the company announced data on joint COVID-19 and flu mRNA vaccine development programs.
  • World Wrestling Entertainment, Inc. WWE rose 17.6% to $84.69 after Vince McMahon announced he has taken actions in support of a plan for WWE to undertake a review of strategic alternatives and capture unique opportunity to maximize long-term value.
  • Oxbridge Re Holdings Limited OXBR gained 16.8% to $1.80.
  • Sensus Healthcare, Inc. SRTS jumped 16.6% to $8.60. Sensus Healthcare expects Q4 sales to exceed $13 million.
  • TCR2 Therapeutics Inc. TCRR gained 16.5% to $1.27. Piper Sandler maintained TCR2 Therapeutics with an Overweight and raised the price target from $8 to $10.
  • Magic Empire Global Limited MEGL rose 13.9% to $2.6199 after climbing 75% on Thursday.
  • Mullen Automotive, Inc. MULN gained 13.8% to $0.4762.
  • Aethlon Medical, Inc. AEMD shares rose 13.2% to $0.39. Aethlon Medical, last month, posted a Q2 loss of $0.18 per share.
  • Duck Creek Technologies, Inc. DCT gained 12.5% to $12.69 following Q1 results.
  • Amarin Corporation plc AMRN gained 12.3% to $1.4150 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $1.3 to $3.
  • JinkoSolar Holding Co., Ltd. JKS rose 11.8% to $44.69.
  • Immunome, Inc. IMNM shares gained 11.2% to $5.24 after the company and AbbVie announced a strategic collaboration to discover multiple novel oncology targets. Immunome will receive a $30 million upfront payment with the potential for milestones and royalties.
  • Oriental Culture Holding LTD OCG gained 10% to $0.55.
  • eFFECTOR Therapeutics, Inc. EFTR rose 8% to $0.5958. eFFECTOR Therapeutics provided an update on its ongoing clinical development programs for zotatifin, in Phase 2 expansion cohorts for estrogen receptor-positive breast cancer (ER+ BC) and KRAS non-small cell lung cancer (KRAS NSCLC) as well as Phase 1 development for COVID-19, and tomivosertib, in Phase 2b trial for non-small cell lung cancer (NSCLC) in combination with pembrolizumab.


  • Fate Therapeutics, Inc. FATE shares dipped 62.2% to $4.16 after the company announced termination
  • of its collaboration agreement with Janssen, pipeline prioritization, next-generation programs and key 2023 initiatives.
  • Graphite Bio, Inc. GRPH fell 41.3% to $1.7950 after the company reported it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease due to a serious adverse event in the first patient dosed with nula-cel.
  • Atai Life Sciences N.V. ATAI fell 41.3% to $1.5450 after the company announced Perception Neuroscience's Phase 2a clinical trial did not meet its primary endpoint.
  • Nabriva Therapeutics plc NBRV dropped 33.4% to $1.5238 after the company issued a corporate update.
  • AnaptysBio, Inc. ANAB declined 28.8% to $21.49 after the company announced portfolio update across best-in-class immune cell modulating antibodies. Raymond James downgraded AnaptysBio from Outperform to Market Perform.
  • NextPlay Technologies, Inc. NXTP fell 25.9% to $1.63. NextPlay announced a 1-for-20 reverse stock split effective January 6, 2023.
  • Landos Biopharma, Inc. LABP fell 24.7% to $0.4086 after Jefferies downgraded the stock from Hold to Underperform and lowered its price target from $0.20 to $0.10.
  • AMTD Digital Inc. HKD shares fell 24.5% to $22.54 after surging around 200% on Thursday.
  • Elevation Oncology, Inc. ELEV declined 20% to $0.8395 after the company reported pipeline prioritization, realignment of resources to advance EO-3021 and CEO transition.
  • Tian Ruixiang Holdings Ltd TIRX dropped 20% to $2.60.
  • Vivos Therapeutics, Inc. VVOS dropped 19.1% to $1.52. Vivos Therapeutics priced an $8 million private placement at $1.20 per unit.
  • Moolec Science SA MLEC declined 17.8% to $4.50.
  • Genprex, Inc. GNPX dropped 17.6% to $1.4225.
  • Bed Bath & Beyond Inc. BBBY fell 16.9% to $1.4050 after dropping around 30% on Thursday. The company said it will miss its 10-Q filing deadline for the quarter ending Nov 26, 2022 and has also concluded that there is substantial doubt about its ability to continue as a going concern.
  • Kiora Pharmaceuticals, Inc. KPRX declined 15.4% to $3.90.
  • XPeng Inc. XPEV fell 15% to $10.11.
  • Palisade Bio, Inc. PALI dropped 14.8% to $2.76.
  • Eloxx Pharmaceuticals, Inc. ELOX fell 14.5% to $3.6913.
  • The Greenbrier Companies, Inc. GBX dropped 14% to $30.00 after the company reported Q1 earnings results and issued guidance.
  • Kura Sushi USA, Inc. KRUS fell 13% to $42.11 after the company reported worse-than-expected Q1 EPS and sales results.
  • InMed Pharmaceuticals Inc. INM fell 13% to $1.68 after declining over 11% on Thursday.
  • Vyant Bio, Inc. VYNT fell 12.3% to $1.06. Vyant Bio shares jumped around 57% on Thursday after the company engaged LifeSci Capital as its advisor to explore strategic alternatives.
  • Orchard Therapeutics plc ORTX shares fell 11.3% to $0.5583. Orchard Therapeutics shares gained around 22% on Thursday after the company announced FDA clearance of the IND application for OTL-203 in MPS-IH.
  • ABVC BioPharma, Inc. ABVC fell 11.2% to $0.9501. ABVC BioPharma shares climbed over 72% on Thursday after the company announced the FDA approved its IND submission, allowing the company to proceed with the clinical study of ABV-1519 for the treatment of non-small cell lung cancer.
  • Waters Corporation WAT declined 9.9% to $312.79. SVB Leerink maintained Waters with a Market Perform and raised the price target from $320 to $352.
  • Silvergate Capital Corporation SI dropped 9.5% to $11.37 after multiple firms downgraded the stock and lowered their respective price target.

Also Check This Out Ethereum Remains Above This Key Level; TRON Becomes Top Loser

Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksSmall CapIntraday UpdateMarketsMoversTrading IdeasMid-Day MoversTop Gainers
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!